Home

AtriCure has announced that the first patient was treated in the LeAAPS clinical trial, a prospective, randomised clinical trial to evaluate the safety and effectiveness of the AtriClip (Atricure) left atrial appendage (LAA) exclusion system for the prevention of ischaemic stroke or systemic arterial embolism in cardiac surgery patients at elevated risk for these events and with no history of atrial fibrillation (AF).

The patient was treated by US co-principal investigator Marc Gerdisch at Franciscan St Francis Heart Center in Indianapolis. The trial will enrol up to 6,500 patients at up to 250 centers worldwide, making it the largest randomised clinical trial for surgical LAA exclusion. LeAAPS is intended to inform and better define clinical practice and treatment guidelines for stroke prevention in patients undergoing planned cardiac surgery with an elevated risk of ischaemic stroke and systemic embolism.

“The LeAAPS trial is a landmark study to evaluate the prophylactic use of AtriClip devices for stroke reduction in cardiac surgery patients without a preoperative AF diagnosis, laying the groundwork for a new frontier in stroke prevention,” said Michael Carrel, president and CEO of AtriCure.

AtriCure first entered the LAA market upon US Food and Drug Administration (FDA) 510(k) clearance of the AtriClip System in 2010. AtriCure plans to use LeAAPS trial results to expand the labelled indications for use of the AtriClip system to include stroke prevention in patients with elevated risk of ischaemic stroke events.

The trial will be completed in collaboration with the Population Health Research Institute (PHRI), which is associated with McMaster University in Hamilton, Canada. PHRI is a clinical research organisation that has organised an extensive international network of committed collaborators in 102 countries. PHRI has significant experience and expertise designing and executing large, clinical studies.

“LeAAPS is one the largest randomised controlled trials in cardiac device history, and we expect it will establish a new standard of care for patients undergoing cardiac surgery,” said Richard Whitlock, a cardiothoracic surgeon at McMaster University and the global principal investigator for the trial. “A fantastic multidisciplinary team has designed the trial, and we are all excited to advance the understanding of atrial disease, atrial fibrillation and stroke.”

Whitlock detailed the goals of the trial in a presentation at the 2022 European Association of Cardio-Thoracic Surgery (EACTS) annual meeting (5–8 October, Milan Italy). The study follows on from LAAOS III, in which investigators studied surgical LAAO in patients undergoing valve or coronary artery bypass graft (CABG) surgery with documented atrial fibrillation or atrial flutter and a CHA₂DS₂-VASc score of two or higher, indicating an elevated risk of stroke.

Source Cardiovascular News

Duc Tin Clinic

Chia sẽ qua facebook bài: First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery patients

Chia sẽ qua google bài: First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery patients

Chia sẽ qua twitter bài: First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery patients

Chia sẽ qua MySpace bài: First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery patients

Chia sẽ qua LinkedIn bài: First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery patients

Chia sẽ qua stumbleupon bài: First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery patients

Chia sẽ qua icio bài: First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery patients

Chia sẽ qua digg bài: First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery patients

Chia sẽ qua yahoo bài: First patient treated in LeAAPS trial of left atrial appendage occlusion in cardiac surgery patients

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.